AL AMYLOIDOSIS
Clinical trials for AL AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new AL AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for AL AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New antibody combo aims to tame rare blood disease
Disease control OngoingThis early-phase trial tests whether adding the drug isatuximab to standard chemotherapy can safely treat people with high-risk AL amyloidosis, a rare disease where abnormal proteins damage organs. Eleven participants will receive the combination to see if it reduces toxicity and…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 23, 2026 21:03 UTC
-
Could a maintenance drug keep AL amyloidosis at bay?
Disease control OngoingThis phase 2 trial is testing whether the oral chemotherapy drug ixazomib can help control AL amyloidosis after initial treatment. Seventeen adults with the disease will take ixazomib along with low-dose dexamethasone to see if it delays organ progression or the need for more the…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
New hope for AL amyloidosis patients who failed first-line therapy
Disease control OngoingThis study tests whether adding daratumumab back to pomalidomide and dexamethasone can improve complete remission rates in 15 adults with relapsed or refractory AL amyloidosis who have already received daratumumab. Participants receive the three-drug combination to control the di…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
New antibody therapy targets Hard-to-Treat AL amyloidosis
Disease control TerminatedThis trial aimed to test an experimental drug called CM-336 for people with AL amyloidosis that has returned, not responded to treatment, or only partially responded after initial therapy. The drug works by helping the immune system attack and destroy harmful cells. However, the …
Matched conditions: AL AMYLOIDOSIS
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 17, 2026 12:06 UTC
-
New antibody could clear toxic proteins from organs in rare disease
Disease control OngoingThis study tests an experimental drug called CAEL-101 in 125 people with a rare disease called AL amyloidosis, where abnormal proteins build up in organs like the heart and kidneys. The drug is designed to remove those protein deposits. The goal is to see if it helps people live …
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 17, 2026 12:04 UTC
-
New hope for amyloidosis patients: Long-Term safety study of AT-02 underway
Disease control OngoingThis study is for people with systemic amyloidosis, a disease where abnormal proteins build up in organs. It tests the long-term safety of an experimental drug called AT-02. About 120 adults will receive the drug and be monitored for side effects and how the drug behaves in the b…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Attralus, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
New drug could clear toxic proteins from organs in rare disease
Disease control OngoingThis study tests an experimental drug called CAEL-101 in 281 people with AL amyloidosis, a rare disease where abnormal proteins build up in organs like the heart and kidneys. The drug aims to remove these protein deposits, potentially helping patients live longer and avoid heart-…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 02, 2026 11:58 UTC
-
New drug aims to reduce pain and fatigue after stem cell transplant in older patients
Symptom relief OngoingThis study tests whether a drug called siltuximab can reduce symptoms like weakness, fatigue, nausea, and pain after a stem cell transplant in patients aged 60-75 with multiple myeloma or AL amyloidosis. The drug blocks a protein linked to inflammation, which may help patients re…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 16, 2026 12:50 UTC